Pipeline & Products

Arovella is developing its iNKT cell therapy platform to treat blood cancers and solid tumours.

Illustration of an INKT cell with an attached TCR receptor, adjacent to a red blood cell, depicting immune response to a COVID-19 infection with a depiction of a COVID-19 virus particle.

ALA-101 CD19-targeting CAR-iNKT cells

ALA-101 is a next-generation "off-the-shelf" CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias. 

A scientific illustration of an INKT cell, a T cell, and a bacteria, with labels pointing to each component. The INKT cell is depicted with internal blue structures, the T cell with an arm and red two-pronged structure, and the bacteria with pink spots inside a dark blue shape. The diagram also shows a car labeled 'CLDN18.2 CAR' and a diagram of a TCR, or T cell receptor.

ALA-105 CLDN18.2-targeting CAR-iNKT cells   

Arovella has entered into a global, exclusive license with Sparx Group to develop a world-first iNKT cell therapy targeting Claudin 18.2 (CLDN18.2), which is expressed in gastric cancer (GC), gastroesophageal junction cancer (GEJC) and pancreatic cancer (PC). 

Learn more about our iNKT cell technology and grasp its future potential in the fight against cancer.